Plasma cyclic nucleotide levels in acute leukemia patients. 1987

M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli

To verify the clinical usefulness of extracellular cyclic nucleotide determination as a tumor marker, plasma cyclic AMP (cAMP) and cyclic GMP (cGMP) levels were measured in 70 normal subjects and 173 acute leukemia patients studied in different stages of their disease. Mean plasma cAMP levels were similar in leukemic and normal subjects, although in 48 patients in the active stage of the disease, first diagnosis, or relapse, the cAMP values were below the normal range, and most of these patients failed to respond to chemotherapy. Plasma cGMP levels were markedly elevated in untreated patients, normalized in all patients who attained complete remission, and increased promptly to pretreatment values in patients who relapsed, suggesting that their determination may be useful to monitor the patients' response to treatment.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009712 Nucleotides, Cyclic Cyclic Nucleotide,Cyclic Nucleotides,Nucleotide, Cyclic
D005260 Female Females
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
January 1979, Acta endocrinologica,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
November 1981, Thorax,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
October 1977, Diabetes,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
January 1984, Cancer,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
March 1990, Blut,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
October 1983, Bulletin of the Osaka Medical School,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
January 1961, The Journal of the Albert Einstein Medical Center, Philadelphia,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
October 1981, Experimental cell research,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
May 1987, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
M Peracchi, and V Toschi, and F Bamonti-Catena, and L Lombardi, and B Bareggi, and A Cortelezzi, and M Colombi, and A T Maiolo, and E E Polli
May 1976, Biochimica et biophysica acta,
Copied contents to your clipboard!